Health
CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV – Press Release – Digital Journal
Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Rolling submission with EMA initiated to accelerate time to potential marketing authorization of CVnCoV
- Submission of CVnCoV pre-clinical data package marks start of the rolling process
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / February 12, 2021 / CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced initiation of a rolling submission with the European Medicines Agency (EMA)…
Continue Reading
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Noosa News19 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News23 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call
-
General19 hours agoInternal Revenue Service starts cutting 20,000 workers